Browsing Category
Pharma Industry News
4720 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
What Restora Neurosciences reveals about the next financing model for psychedelic-adjacent CNS biotech
What does Restora Neurosciences reveal about the future of CNS biotech financing? Read the full Business News Today analysis.
Can Namodenoson overcome immunotherapy resistance in advanced pancreatic adenocarcinoma?
Can-Fite BioPharma Ltd. advances Namodenoson into Phase 2b pancreatic cancer testing. Discover what this means for immunotherapy economics.
What the latest ALICE-2 and FRIDA trial results reveal about iadademstat’s AML potential
What do the latest ALICE-2 and FRIDA trial results reveal about iadademstat’s AML potential? Explore the strategic and market implications now.
Genentech secures first ctDNA MRD-guided therapy approval for Tecentriq in MIBC
A cancer drug win is only half the story. Roche and Natera are testing whether ctDNA can decide who truly needs treatment.
Atrium Therapeutics (Nasdaq: RNA) Q1 results show cash runway and clinical urgency behind precision cardiology bet
Atrium has cash and RNA ambition. The harder test is whether heart-targeted delivery can turn rare cardiomyopathy science into clinical proof.
Racura Oncology (ASX: RAC) stock up 12.21% as MYC silencing data builds case for bisantrene relaunch
MYC is the undruggable cancer gene. Racura Oncology (ASX: RAC) says bisantrene silences it via G4 stabilisation. Three clinical trials, A$19m cash, and a 2027 inflection ahead.
Kelun-Biotech advances SKB118 in China as PD-1 x VEGF race intensifies
Kelun-Biotech has the platform. SKB118 tests whether PD-1 x VEGF can deepen its ADC-led oncology strategy in China.
What the Acclaim cochlear implant’s pivotal data could mean for the broader hearing device market
Could Envoy Medical, Inc.’s Acclaim implant reshape the hearing-device market? Explore the regulatory, commercial, and industry implications.
Could oral elraglusib emerge as a combination backbone for RAS-targeted cancer therapies?
Actuate Therapeutics, Inc. is advancing oral elraglusib to target resistance biology in cancer. Discover what this means for oncology markets.
Insmed (NASDAQ: INSM) rebounds as retail eyes ATS 2026 readouts after Q1 reset
INSM bounced 11% after a 20% post-earnings reset. BRINSUPRI is launching faster than any respiratory drug in a decade. So why did the market sell the print?